ANIMALHEALTHX Weekly is your weekly pulse on the global animal health industry, delivering curated insights, executive interviews, regulatory updates, innovation breakthroughs, and market movements shaping the future of veterinary medicine and animal care.
Feature Article
- Trends Shaping the Global Animal Healthcare Market: A Transformative Shift
A deep dive into the key forces redefining animal healthcare, from pet humanization and preventive care to AI-driven innovation and sustainable livestock practices.
Cover Story
- Prange Pharma Expands European Footprint with Strategic Veterinary CDMO Hub
Strategic acquisition of MSD Animal Health’s Aprilia site to establish a leading veterinary CDMO platform in Aprilia.
Product Launches & Innovations
- IFF Introduces PureStrong Canine Probiotic
Species-specific microbiome innovation for targeted digestive health in dogs. - VetVerifi Launches SmartTag for Vaccine Record Digitization
Enhancing clinic connectivity and simplifying pet health record management. - Parnell Launches nixiFLOR for Bovine Respiratory Disease
First FDA-approved generic alternative improving cost efficiency and treatment ease.
Clinical & R&D Developments
- Can-Fite & Vetbiolix Complete Phase 2 Enrollment for Piclidenoson
Advancing oral treatment options for canine osteoarthritis with novel anti-inflammatory mechanisms. - IDEXX Expands Cancer Dx Panel to the UK
Enabling early detection of canine lymphoma through routine blood-based screening.
Corporate & Strategic Updates
- Axiota Animal Health Establishes Global HQ in Wamego, Kansas
Strengthening global livestock innovation and non-antibiotic solutions. - Royal Agrifirm Group to Acquire Hamlet Protein
Expanding capabilities in early-life animal nutrition and gut health solutions.
Prange Pharma Turns MSD’s Aprilia Site into European Veterinary CDMO Hub
Prange Pharma has completed the acquisition of MSD Animal Health’s manufacturing site in Aprilia, marking a strategic step in strengthening its presence in the European animal healthcare market. The facility will now operate as Aprilia Animal Health, a dedicated contract development and manufacturing organization (CDMO) platform focused exclusively on veterinary pharmaceuticals.
Key Highlights
The Aprilia site brings over 65 years of manufacturing expertise, supported by a highly skilled workforce of approximately 120 employees. Its capabilities span both sterile and non-sterile manufacturing and filling, including specialized segments such as beta-lactam antibiotics and ectoparasiticides—positioning it as a versatile hub for diverse animal health needs.
Aprilia Animal Health will cater to both Prange Pharma’s internal product portfolio and third-party clients, offering flexible and scalable CDMO solutions to global animal health companies. The long-term supply agreement with MSD Animal Health ensures continuity for existing products while enabling a seamless transition and sustained market supply.
Prange Pharma has outlined plans for continued investment and integration, aiming to transform the Aprilia facility into a center of excellence in veterinary contract manufacturing. This move aligns with increasing industry demand for outsourced manufacturing capabilities and the need for resilient, localized supply chains across Europe.
Impact
This acquisition significantly strengthens Prange Pharma’s European manufacturing network while reflecting the growing shift toward specialized CDMO partnerships in the animal health sector. As companies seek greater agility, faster time-to-market, and dependable global supply, such strategic expansions are set to play a pivotal role in shaping the future of veterinary pharmaceuticals.
Trends Shaping the Global Animal Healthcare Market: A Transformative Shift
The global animal healthcare market is undergoing a significant transformation, driven by evolving consumer attitudes, technological innovation, and increasing awareness of animal well-being. Animals—whether companion pets or livestock—are now seen as integral to human life, creating a growing demand for advanced, accessible, and preventive healthcare solutions.
One of the most prominent trends is the rising humanization of pets. Pet owners are increasingly willing to invest in high-quality healthcare, mirroring the standards of human medicine. This shift has led to greater demand for advanced diagnostics, specialty treatments, and personalized care plans. Veterinary services are expanding beyond routine check-ups to include dermatology, oncology, orthopedics, and even rehabilitation therapies.
Preventive care continues to gain momentum as a cornerstone of animal health. Vaccination programs, parasite management, and routine screenings are becoming standard practice across both companion and production animals. Early disease detection not only improves outcomes but also reduces the economic burden associated with late-stage treatments, particularly in livestock management.
Technological innovation is rapidly reshaping the landscape. Digital tools such as tele-veterinary services, wearable health monitors, and AI-driven diagnostic platforms are enabling more precise and timely interventions. These advancements empower veterinarians with data-driven insights while allowing pet owners and farmers to monitor animal health in real time.
Another key driver is the growing focus on food safety and sustainable livestock production. As global demand for protein rises, maintaining the health of farm animals is critical to ensuring safe and efficient food supply chains. This has accelerated the adoption of vaccines, biologics, and alternatives to antibiotics, aligning with regulatory efforts to combat antimicrobial resistance.
The market is also witnessing increased investment in research and development. Pharmaceutical companies and biotech firms are actively developing novel therapies, including biologics and gene-based treatments, to address complex diseases in animals. This innovation pipeline is expanding treatment possibilities and improving overall care standards.
In essence, the animal healthcare market is evolving from a traditionally reactive model to one that emphasizes prevention, precision, and sustainability. As these trends continue to shape the industry, the focus remains clear: healthier animals contribute to healthier ecosystems, safer food systems, and stronger human-animal bonds worldwide.
M&A Update
Royal Agrifirm Group has agreed to acquire Hamlet Protein, a global producer of specialty soy-based protein ingredients for young animal nutrition, in a deal that will be integrated into Agrifirm’s Specialties business.
Key Highlights
- Hamlet Protein’s highly digestible soy-based ingredients support gut health, early growth, and feed efficiency in young animals, underpinned by patented processing technology and production sites in Denmark and the United States plus a commercial presence in China and about 115 employees.
- The acquisition complements Agrifirm’s portfolio of premixes, concentrates, functional feed ingredients, farm minerals, and young animal nutrition concepts, enabling more integrated, science-based early-life feeding solutions.
- Hamlet Protein will continue to operate under its own brand while leveraging Agrifirm’s global distribution, technical expertise, and customer network to accelerate innovation and scale high-digestibility solutions worldwide.
Impact
Strengthens Agrifirm’s position in precision early-life nutrition and reflects broader industry moves toward gut-health-focused, value-added feed solutions that support lifetime productivity and more sustainable animal production.
Product Launch
IFF has introduced PureStrong, a next-generation probiotic developed specifically from the canine microbiome to support dog digestive health, as part of its HOWARU Pet platform.
Key Highlights
- PureStrong contains a single targeted strain of Limosilactobacillus reuteri isolated from dogs, designed to efficiently survive and colonize the canine gut, deliver low-dose efficacy, and simplify formulations for pet brands.
- Positioned within IFF’s science-backed HOWARU Pet portfolio for dogs and cats, the product supports gut health and digestive comfort under real-world conditions such as diet change, travel, and aging.
- In controlled feeding studies, dogs receiving PureStrong during dietary transitions showed improved digestive markers, better hydration and diet tolerance, and firmer but non-constipated stools, underscoring tangible gut-health benefits.
Impact
Advances the shift toward species-specific, microbiome-driven pet supplements, meeting growing demand for evidence-based, precision probiotics as pet owners seek more targeted, human-grade nutrition solutions for their dogs.
Clinical Development
Can-Fite BioPharma’s veterinary partner Vetbiolix has completed enrollment of 118 client-owned dogs in a randomized, double-blind, placebo-controlled Phase 2 trial evaluating oral Piclidenoson for canine osteoarthritis, with top-line data expected in Q3 2026.
Key Highlights
- The 90-day study uses twice-daily oral dosing and assesses efficacy via the Liverpool Osteoarthritis in Dogs (LOAD) questionnaire as the primary endpoint, supported by owner-reported pain on a Visual Analog Scale and veterinarian-assessed lameness and discomfort on a Numerical Rating Score.
- Vetbiolix has exercised its option to fully license Piclidenoson for veterinary use, taking on development and regulatory responsibilities, while Can-Fite is eligible for upfront and milestone payments plus royalties, with potential revenues of up to 325 million dollars over 10 years tied to successful approval and commercialization.
- Targeting a canine osteoarthritis market projected to approach 3 billion dollars by 2028, Piclidenoson’s novel anti-inflammatory mechanism is being positioned as a differentiated, convenient oral alternative to existing symptomatic treatments such as NSAIDs, anti-NGF agents, and EP4 antagonists.
Impact
If successful, the program could expand long-term management options for one of the most common chronic conditions in dogs, aligning with a broader industry push toward mechanism-driven, safer oral therapies in veterinary pain and inflammation.
Product Launch
VetVerifi has launched SmartTag, a connected vaccine tag that links a pet’s verified vaccination records directly to their primary clinic, aiming to streamline record management and strengthen clinic–client relationships.
Key Highlights
- SmartTag centralizes vaccination data that is often scattered across emails, paper forms, and third-party apps, giving pet owners instant access to real-time, clinic-verified records via a simple scan.
- Clinics redirect vaccine verification requests (e.g., from groomers or boarding facilities) to VetVerifi, which manages these inquiries, identifies care gaps such as overdue vaccines, and helps convert them into follow-up appointments.
- By offloading verification and record-sharing tasks, SmartTag reduces front-desk workload while helping practices maintain visibility into where and when pets receive care, supporting better continuity and long-term client retention.
Impact
Supports the broader digitization of veterinary care by keeping data tied to the primary clinic, enabling more proactive preventive care and allowing practices to compete on a modern, seamless client experience as pet owners demand greater convenience.
Product Expansion
IDEXX Laboratories has launched its IDEXX Cancer Dx Panel in the United Kingdom, offering veterinary practices a blood-based test that supports early detection of lymphoma in dogs, with results available in approximately 3–5 business days.
Key Highlights
- The panel is designed to integrate into routine wellness and diagnostic panels, detecting a lymphoma signal up to eight months before clinical signs appear, and has already been adopted by nearly 6,000 practices in North America since its 2025 debut.
- Performance metrics include 79 percent sensitivity and 99 percent specificity, delivered via a single blood draw that can also provide qualitative information such as likely Bcell or Tcell lymphoma classification and support for treatment monitoring.
- Research shows that 71 percent of UK pet owners are open to cancer screening for their pets, underscoring strong demand for proactive oncology solutions that IDEXX plans to build on by expanding the Cancer Dx Panel to cover a broader range of canine cancers over the next three years.
Impact
Supports the shift toward preventive oncology in veterinary medicine by embedding advanced cancer screening into everyday workflows, enabling earlier diagnosis, more informed treatment decisions, and the potential for improved outcomes and quality of life in dogs.
Product Launch
Parnell has launched nixiFLOR in the US, an FDA-approved injectable solution for the treatment of bovine respiratory disease (BRD) and control of BRD-associated fever in beef and non-lactating dairy cattle, marking the first generic equivalent to Resflor Gold.
Key Highlights
- nixiFLOR combines florfenicol, an antimicrobial targeting BRD pathogens, with flunixin meglumine, a non-steroidal anti-inflammatory that reduces fever and inflammation, administered as a single subcutaneous injection in the neck.
- The FDA has determined nixiFLOR to be bioequivalent to Resflor Gold, providing comparable safety and effectiveness while offering a more cost-efficient option for veterinarians and producers.
- Single-dose administration helps streamline BRD treatment protocols by reducing chute time, labor, and dosing complexity, supporting more efficient disease management in large herds.
Impact
Improves access to an effective dual-action BRD therapy while easing cost pressures and operational burdens, aligning with industry efforts to balance animal welfare, productivity, and economic sustainability in cattle operations.
Animal Healthcare Enters a New Era of Innovation and Precision
The global animal healthcare market is rapidly evolving, driven by pet humanization, preventive care, and digital innovation. This edition highlights key industry shifts alongside major developments, including Prange Pharma’s European CDMO expansion, IFF’s canine probiotic launch, and IDEXX’s early cancer detection panel in the UK. Advances in digital tools, therapeutics, and nutrition are reshaping care delivery. Strategic deals, clinical progress, and product innovations collectively signal a transition toward more precise, data-driven, and sustainable animal healthcare worldwide.
The Pulse of Global Animal Health
Enjoyed this edition? Share it with colleagues, partners, and fellow leaders shaping the future of animal health.
The industry is evolving at remarkable speed—from breakthrough biotech partnerships and regulatory milestones to AI-driven diagnostics and next-generation veterinary innovations. Staying informed isn’t just valuable—it’s essential to staying ahead.
Forward this newsletter, repost it, and help foster a more connected, informed, and forward-thinking global animal health community.
